Case Page

 

Case Status:    ONGOING    
On or around 12/13/2016 (Ongoing date of last review)

Filing Date: July 12, 2016

According to a law firm's press release, the Complaint alleges Juno materially misled investors by failing to disclose the May 2016 death of a patient in the Company’s Phase 2 trial of product candidate JCAR015. These omissions caused Juno to trade at artificially inflated prices, and certain insiders participated in the heavy selling of shares in the weeks prior to the disclosure of the death. Then, following the death of two other patients in June and July, the U.S. Food and Drug Administration issued a clinical hold on the study, and Juno disclosed the patients’ deaths.

On this news, Juno's share price fell significantly in value, dropping almost 32%, or $13.01 per share, to close at $27.81 per share on July 8, 2016.

Then on Wednesday, July 13, 2016, after the close of trading, the Company corrected its prior statement regarding the number of patient deaths, and disclosed that four, not three, patients had died during the clinical trials of JCAR015. On this news, shares of Juno fell as much as 5% during intraday trading on July 14, 2016.

On October 19, 2016, the Court appointed Lead Plaintiff and Counsel.

A consolidated complaint was filed on December 12, 2016.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: JUNO
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: W.D. Washington
DOCKET #: 16-CV-01069
JUDGE: Hon. Ricardo S Martinez
DATE FILED: 07/12/2016
CLASS PERIOD START: 06/04/2016
CLASS PERIOD END: 07/07/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Block & Leviton LLP
    155 Federal Street, Suite 1303, Block & Leviton LLP, MA 02110
    (617) 398-5600 (617) 507-6020 ·
  2. Tousley Brain Stephens PLLC
    1700 Seventh Avenue, Suite 2200 , Tousley Brain Stephens PLLC, WA 98101
    206.682.5600 206.682.5600 · contact@tousley.com
No Document Title Filing Date
COURT: W.D. Washington
DOCKET #: 16-CV-01069
JUDGE: Hon. Ricardo S Martinez
DATE FILED: 12/12/2016
CLASS PERIOD START: 06/04/2016
CLASS PERIOD END: 11/22/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Law Offices Of Clifford A. Cantor, P.C.
    627 208th Ave. SE, Law Offices Of Clifford A. Cantor, P.C., WA 98074
    425.868.7813 425.868.7870 ·
  2. Pomerantz LLP (New York)
    600 Third Avenue, Pomerantz LLP (New York), NY 10016
    212.661.1100 212.661.8665 · info@pomerantzlaw.com/
No Document Title Filing Date